Korea's Celltrion Completes Phase I Clinical Trials For Biosimilars Based On Roche And Johnson & Johnson Products

SEOUL - South Korean biotech firm Celltrion said it has successfully completed Phase I clinical trials on its biosimilar versions of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade(infliximab)